ArticleNucleic acids research2026
riboCIRC v2.0: an expanded resource for translatable CircRNAs.
Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Discovery of a mutation-containing circRNA in polyglutamine disease through systematic analysis of RNAs with CAG repeats.RNA biology · 2026Article
- Noncoding RNA encoded peptides in tumors from discovery to mechanism and clinical translation.iScience · 2026Review
- Review
- Overview of circular RNA databases and other resources.Nature reviews. Molecular cell biology · 2026Article
- The 2026 Nucleic Acids Research database issue and the online molecular biology database collection.Nucleic acids research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
riboCIRC (http://www.ribocirc.com) is a translatome data-oriented database dedicated to cataloging translatable circRNAs and their encoded peptides across six model species, including Homo sapiens, Mus musculus, Rattus norvegicus, Caenorhabditis elegans, Drosophila melanogaster, and Danio rerio. Here, we present riboCIRC v2.0, a major update featuring expanded content and enhanced functionality to facilitate and accelerate research into circRNA translation and function characterization. Key improvements include (i) expanded data coverage: now documenting 5212 computationally predicted translatable circRNAs and 7563 predicted finite ORF-encoded peptides, representing a substantial increase from the initial release (2247 and 2234 entries, respectively); (ii) enhanced evidence integration: incorporation of new evidence layers supporting translation of circRNAs, including RNA editing sites and RBP interactions, supplementing existing evidence from ribosome profiling, mass spectrometry, IRES elements, and m6A modifications; (iii) comprehensive peptide annotation: systematic in silico characterization of finite ORF-encoded peptides, detailing their physicochemical properties, predicted structures, and potential functions; and (iv) optimized user interface: improved navigation and dedicated modules for streamlined data exploration, retrieval, and visualization. Collectively, these enhancements establish riboCIRC v2.0 as a more powerful resource for investigating the functional roles of translatable circRNAs and their products across diverse biological systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.